Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection

Journal of Clinical Virology

Volumn 35, Issue 3, 2006, Pages 324-331

  Wang, Zhongde ^a   La Rosa, Corinna ^a   Lacey, Simon F ^a   Maas, Rebecca ^a   Mekhoubad, Shahram ^a   Britt, William J ^b   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cytomegalovirus; Poxvirus; Transplantation; Vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; GENOMIC DNA; PLASMID DNA; RECOMBINANT VACCINE; UL123 ANTIGEN; UL55 ANTIGEN; UL83 ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BLOOD ANALYSIS; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; GENE DELETION; GENETIC TRANSFECTION; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMID; POXVIRUS; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINIA; VIRUS RECOMBINATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; HUMANS; MICE; PHOSPHOPROTEINS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL MATRIX PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL STRUCTURAL PROTEINS;

EID: 31944436398     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2005.09.018     Document Type: Article

References (48)

1. A.M. Arvin, P. Fast, M. Myers, S. Plotkin, and R. Rabinovich Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee Clin Infect Dis 39 2004 233 239
2. T. Banks, B. Huo, K. Kousoulas, R. Spaete, C. Pachl, and L. Pereira A major neutralizing domain maps within the carboxyl-terminal half of the cleaved cytomegalovirus B glycoprotein J Gen Virol 70 Pt 4 1989 979 985
3. H response Hum Immunol 61 2000 764 779
4. L.K. Borysiewicz, J.K. Hickling, S. Graham, J. Sinclair, M.P. Cranage, and G.L. Smith Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses J Exp Med 168 1988 919 931
5. T. Bunde, A. Kirchner, B. Hoffmeister, D. Habedank, R. Hetzer, and G. Cherepnev Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells J Exp Med 2005
6. M.W. Carroll, and B. Moss E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses Biotechniques 19 1995 352 354 356
7. S. Chakrabarti, K. Brechling, and B. Moss Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques Mol Cell Biol 5 1985 3403 3409
8. A. Cosma, R. Nagaraj, S. Buhler, J. Hinkula, D.H. Busch, and G. Sutter Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals Vaccine 22 2003 21 29
9. *0201 restricted peptide-based vaccine against human cytomegalovirus infection Blood 90 1997 1751 1767
10. I. Drexler, C. Staib, and G. Sutter Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 15 2004 506 512
11. H. Einsele, E. Roosnek, N. Rufer, C. Sinzger, S. Riegler, and J. Loffler Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy Blood 99 2002 3916 3922
12. R. Elkington, S. Walker, T. Crough, M. Menzies, J. Tellam, and M. Bharadwaj Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers J Virol 77 2003 5226 5240
13. V. Endresz, K. Burian, K. Berencsi, Z. Gyulai, L. Kari, and H. Horton Optimization of DNA immunization against human cytomegalovirus Vaccine 19 2001 3972 3980
14. L.J. Geist, and S.L. Hinde Susceptibility to cytomegalovirus infection may be dependent on the cytokine response to the virus J Invest Med 49 2001 434 441
15. M.J. Gilbert, S.R. Riddell, C.R. Li, and P.D. Greenberg Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus J Virol 67 1993 3461 3469
16. E. Gonczol, J. Ianacone, W.Z. Ho, S. Starr, B. Meignier, and S. Plotkin Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers Vaccine 8 1990 130 136
17. E. Gonczol, and S. Plotkin Progress in vaccine development for prevention of human cytomegalovirus infection Curr Top Microbiol Immunol 154 1990 255 274
18. E. Gonczol, and S. Plotkin Development of a cytomegalovirus vaccine: lessons from recent clinical trials Expert Opin Biol Ther 1 2001 401 412
19. F. Kern, I.P. Surel, N. Faulhaber, C. Frommel, J. Schneider-Mergener, and C. Schonemann Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited J Virol 73 1999 8179 8184
20. N. Khan, M. Cobbold, R. Keenan, and P.A. Moss Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype J Infect Dis 185 2002 1025 1034
21. C. La Rosa, Z. Wang, J.C. Brewer, S.F. Lacey, M.C. Villacres, and R. Sharan Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice Blood 100 2002 3681 3689
22. C. La Rosa, Z. Wang, S.F. Lacey, S.F. Markel, M.C. Sharma, and J. Martinez Characterization of Host Immunity to cytomegalovirus pp150 (UL32) Hum Immunol 66 2005 116 126
23. S.F. Lacey, D.J. Diamond, and J.A. Zaia Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants Biol Blood Marrow Transplant 10 2004 433 447
24. A. Mayr, and K. Danner Vaccination against pox diseases under immunosuppressive conditions Dev Biol Stand 41 1978 225 234
25. S.J. McConkey, W.H. Reece, V.S. Moorthy, D. Webster, S. Dunachie, and G. Butcher Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans Nat Med 9 2003 729 735
26. H. Meyer, G. Sutter, and A. Mayr Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence J Gen Virol 72 Pt 5 1991 1031 1038
27. J.D. Meyers Management of cytomegalovirus infection Am J Med 85 1988 102 106
28. J.D. Meyers, N. Flournoy, and E.D. Thomas Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience Rev Infect Dis 4 1982 1119 1132
29. B. Moss, and P.L. Earl J.E. Coligan A.M. Kruisbeek D.H. Margulies E. Shevach W. Strober Expression of proteins in mammalian cells using vaccinia virus vectors 1998 Greene Publishing New York 16.15.1 16.21.9
30. S. Pascolo, N. Bervas, J.M. Ure, A.G. Smith, F.A. Lemonnier, and B. Perarnau HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice J Exp Med 185 1997 2043 2051
31. K.S. Peggs, S. Verfuerth, A. Pizzey, N. Khan, M. Guiver, and P.A. Moss Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines Lancet 362 2003 1375 1377
32. G.V. Quinnan Jr., N. Kirmani, A.H. Rook, J.F. Manischewitz, L. Jackson, and G. Moreschi Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients N Engl J Med 307 1982 7 13
33. M.J. Reddehase Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance Nat Rev Immunol 2 2002 831 844
34. M.J. Reddehase, W. Mutter, K. Munch, H.J. Buhring, and U.H. Koszinowski CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity J Virol 61 1987 3102 3108
35. P. Reusser, S.R. Riddell, J.D. Meyers, and P.D. Greenberg Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease Blood 78 1991 1373 1380
36. S.R. Riddell, M. Rabin, A.P. Geballe, W.J. Britt, and P.D. Greenberg Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression J Immunol 146 1991 2795 2804
37. C. Rochlitz, R. Figlin, P. Squiban, M. Salzberg, M. Pless, and R. Herrmann Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer J Gene Med 5 2003 690 699
38. M.K. Slifka The Future of Smallpox Vaccination: is MVA the key? Med Immunol 4 2005 2
39. C. Slinsky, C. Luke, M. Wloch, A. Geall, G. Hermanson, and D.C. Kaslow A DNA-based vaccine for the prevention of human CMV-associated diseases Hum Vaccines 1 2005 16 23
40. R.R. Spaete A recombinant subunit vaccine approach to HCMV vaccine development Transplant Proc 23 3 1991 90 96
41. S. Stagno, D.W. Reynolds, E.S. Huang, S.D. Thames, R.J. Smith, and C.A. Alford Congenital cytomegalovirus infection N Engl J Med 296 1977 1254 1258
42. U. Utz, W. Britt, L. Vugler, and M. Mach Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus J Virol 63 1989 1995 2001
43. E.A. Walter, P.D. Greenberg, M.J. Gilbert, R.J. Finch, K.S. Watanabe, and E.D. Thomas Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor N Engl J Med 333 1995 1038 1044
44. Z. Wang, C. La Rosa, R. Maas, H. Ly, J. Brewer, and S. Mekhoubad Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus J Virol 78 2004 3965 3976
45. Z. Wang, C. La Rosa, S. Mekhoubad, S.F. Lacey, M.C. Villacres, and S. Markel Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells Blood 104 2004 847 856
46. D.P. Webster, S. Dunachie, J.M. Vuola, T. Berthoud, S. Keating, and S.M. Laidlaw Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara Proc Natl Acad Sci USA 102 2005 4836 4841
47. D.J. Winston, R.P. Gale, D.V. Meyer, and L.S. Young Infectious complications of human bone marrow transplantation Medicine (Baltimore) 58 1979 1 31
48. J.A. Zaia The biology of human cytomegalovirus infection after bone marrow transplantation Int J Cell Cloning 4 Suppl. 1 1986 135 154